M&A Deal Summary |
|
|---|---|
| Date | 2025-06-02 |
| Target | Trelegy Ellipta |
| Sector | Medical Products |
| Buyer(s) | GSK |
| Sellers(s) | Theravance Biopharma |
| Deal Type | Divestiture |
| Deal Value | 225M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1715 |
| Sector | Life Science |
| Employees | 68,629 |
| Revenue | 31.4B GBP (2024) |
GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 35 of 35 |
| Sector: Medical Products M&A | 3 of 3 |
| Type: Divestiture M&A Deals | 7 of 7 |
| Country: United Kingdom M&A | 5 of 5 |
| Year: 2025 M&A | 3 of 3 |
| Size (of disclosed) | 23 of 31 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-05-14 |
Efimosfermin
Cambridge, Massachusetts, United States Efimosfermin is a novel, once-monthly fibroblast growth factor 21 analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis, including cirrhosis, and future development in alcohol-related liver disease. Efimosfermin is based in Cambridge, Massachusetts. |
Buy | $1.2B |
| Category | Company |
|---|---|
| Founded | 2013 |
| Sector | Life Science |
| Employees | 97 |
| Revenue | 64M USD (2024) |
Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance Biopharma was founded in 2013 and is based in George Town, Caymen Islands.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 2 of 2 |
| Country: United Kingdom M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-11-06 |
Theravance Biopharma - VIBATIV
South San Francisco, California, United States Theravance Biopharma, Inc. - VIBATIV is patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin & skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. |
Sell | $20M |
